Obermatt

Phibro Animal Health

NMQ:PAHC · US71742Q1067
PharmaceuticalsMedium

360

59
EV / EBIT73
Price / Owner Earnings37
Owner Earnings Yield69
Dividend Yield95
Price/Sales93
EV / Gross Profit49
Price/Book48
Return on Capital95
Cash Return on Capital64
Return on Equity92
EBIT Margin59
Gross Profitability60
Cash Conversion16
Accruals29
Owner Earnings Margin45
Sales growth66
Profit Growth76
Long-Term EPS Growth84
Owner Earnings Growth79
Reinvestment48
Price momentum55
Debt load15
Refinancing98
Debt Payback19
Liquidity73
Analyst ratings1
Opinion Changes50
Price Target Upside48
Market mood52
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Phibro Animal Health generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded1946
Employees1,161
Websitepahc.com
ISINUS71742Q1067
Last UpdateApr 2, 2026
Themes
NutraceuticalPain ManagementAquacultureFarmingPet Food and SuppliesAnimal FeedLivestockVaccinesFarmers MarketFood Processing

Description

Phibro Animal Health Corporation operates as a global diversified animal health and mineral nutrition company. The company strives to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise and care for farm an…

Analysis

Middle-of-the-road

Phibro Animal Health Corporation is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is attractive. You pay 13.9× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly 1% yearly growth; analysts expect 21%. The price, in other words, assumes less than the experts do.

The trajectory is solid and the balance sheet is stretched. The company scores 16/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
88
2023202420252026

All-time high

100

Jan 2026

All-time low

66

Jan 2024

Average rank

84

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
80
93
96
Price/Earnings
40
58
69
59
Price/Book
48
35
50
39
Dividend Yield
95
88
92
98
Value (overall)
98
96
99
100

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Phibro Animal Health with its peers
Elanco Animal Health
NYQ:ELAN
10
CountryUSA
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Zoetis
NYQ:ZTS
56
CountryUSA
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Merck (USA)
NYQ:MRK
35
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Ligand Pharmaceuticals
NMQ:LGND
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Collegium Pharmaceutical
NSQ:COLL
100
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Cybin
NEO:HELP
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →